Nocion Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel small molecule charged sodium channel blockers called “nocions”, that selectively silence actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain, announced that it had appointed Joan Shaw to Senior Vice President, Clinical Operations. Shaw held leadership roles in the successful clinical development of camlipixant for persistent cough as members of the Bellus Health clinical team.
“We are delighted to welcome Joan to our scientific/clinical teams as we prepare for the start of our ASPIRE (Phase 2b) clinical trial of Taplucainium in 240 chronic cough patients in the second half of 2024,” said Rick Batycky, CEO of Nocion Therapeutics. “Joan have unique and successful experiences in the area of therapeutic development for chronic cough. These experience is immediately applicable to our development of Taplucainium for patients suffering from chronic cough.”
Joan Shaw Bio
Prior to joining Nocion, Joan served as the SVP of Clinical Operation at Bellus Health (now GSK) and established their global late-stage drug development strategy for refractory chronic cough, completed their successful Phase 2b study and initiated a program of Phase 3 studies. She has a unique combination of experiences with large pharmaceutical companies (Astra Zeneca, DuPont Pharma, Takeda), biotech companies (Bellus Health, Agenus) and contract research organizations (Parexel, UBC, Quotient Sciences) in multiple therapeutic areas spanning over 30 years.
Joan is a licensed Medical Technologist (B.S., University of Delaware) and an MS in Clinical Chemistry (West Chester University) and holds a Six Sigma Black Belt (Villanova).
Nocion Therapeutics is a biopharmaceutical company developing novel small molecule charged sodium channel blockers called “nocions” that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons.
SOURCE: Businesswire